Eli Lilly and Company (LLY)
Bull Thesis
- Tirzepatide dominance: Mounjaro and Zepbound combined for $36.5B in FY 2025 revenue — the world's best-selling drug — and accelerated to ~$15B in Q2 2026 alone.1
- Oral GLP-1 first-mover: Foundayo (orforglipron) received FDA approval April 1, 2026, as the only GLP-1 pill takeable any time without food/water restrictions, opening a massive new market segment.2
- Guidance momentum: Lilly raised FY 2026 revenue guidance twice, landing at $85–87B; non-GAAP EPS guide raised to $35.50–$36.50, with operating margin expanding to 49–50.5%.3
- Deep pipeline diversification: Beyond GLP-1, positive Phase 3 results for retatrutide (diabetes), Jaypirca combinations (blood cancer), and over 3,200 clinical trials support a multi-decade growth runway.4
- Manufacturing scale-up: $750M Resilience CDMO partnership (July 2026), $3B China expansion, $3B Netherlands facility, and $1B India partnership ensure supply can match surging demand.5
Bear Thesis
- Tirzepatide concentration risk: Mounjaro and Zepbound together represent ~65% of Q2 2026 revenue; any safety signal, competitive setback, or pricing compression would materially impair earnings.6
- Patent cliff exposure: Generic challengers filed 14 patent suits against Lilly by August 2026; once tirzepatide patents expire, biosimilar entry could dramatically compress margins.7
- Pricing pressure: Q1 2026 revenue was partially offset by lower realized prices from Mounjaro and Zepbound; IRA drug-pricing negotiations and payer contracting are structural headwinds.8
- Compounding competition: FDA-authorized compounders have been supplying cheaper versions of semaglutide and tirzepatide; while Lilly is litigating aggressively, compounding represents near-term demand leakage.7
- Elevated valuation: At ~$1.06T market cap and trading at a large premium to large-cap pharma peers, any guidance miss, clinical failure, or macro shock could trigger a sharp multiple compression.9
Executive Summary
Eli Lilly and Company is a 150-year-old Indianapolis-based pharmaceutical company that has transformed into the world's most valuable drug maker on the back of tirzepatide — a dual GIP/GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity.10 Founded in 1876 by Colonel Eli Lilly, the company today operates across four primary therapeutic areas: cardiometabolic health, oncology, neuroscience, and immunology.11
The fundamental snapshot is exceptional by any historical pharmaceutical standard. FY 2025 revenue reached $65.18 billion, a 45% increase year-over-year, with net income of $20.64 billion — a 95% jump from 2024's $10.6 billion.12 That momentum accelerated into 2026: Q2 2026 revenue hit $23.0 billion, up 48% year-over-year, with non-GAAP EPS of $8.38 beating consensus by $2.31.13 Lilly raised its full-year 2026 revenue guidance — for the second time — to $85–87 billion, with operating margin guided to 49.0–50.5%.3 The company became the first pharmaceutical firm in history to cross a $1 trillion market capitalization.9
The bull case rests on three questions: Can tirzepatide continue to take global market share in diabetes and obesity while maintaining pricing? Can Foundayo (the oral GLP-1, approved April 2026) scale into a separate blockbuster? And can Lilly's diversified pipeline — retatrutide, orforglipron in diabetes, Jaypirca expansions, and a wave of acquired early-stage assets — sustain growth through the 2030s when tirzepatide patents face generic challenges? The bear case requires believing the company's product concentration (two drugs making up ~65% of revenue) is an underappreciated risk, that payer pricing pressure will compress realized prices faster than volume grows, and that generic/compounding threats will erode the franchise before next-generation replacements mature.67
Company History & Leadership
Eli Lilly and Company was founded on May 10, 1876, in Indianapolis, Indiana, by Colonel Eli Lilly — a pharmaceutical chemist and Civil War veteran who was 38 years old at the time.11 Under the colonel's leadership, the company pioneered systematic drug production in the United States, employing more than 100 people and generating $300,000 in annual revenue by the time of his death in 1898.11 Today, headquartered in Indianapolis, Lilly is one of the world's largest pharmaceutical companies and the first to reach a $1 trillion market capitalization in the sector.9
Leadership
| Name | Title | Since | Notes |
|---|---|---|---|
| David A. Ricks | Chair & Chief Executive Officer | 2017 | Has led the company through its transformation into the world's most valuable pharmaceutical firm |
| Anat Ashkenazi | Senior VP & Chief Financial Officer | — | Oversees financial strategy during a period of record revenue growth |
| Daniel Skovronsky, MD, PhD | Chief Scientific & Medical Officer | — | Leads R&D strategy across metabolic disease, oncology, and neuroscience |
| Ilya Yuffa | Executive VP, Lilly International | — | Leads international commercial operations including GLP-1 expansion in China and Europe |
Business Model & Unit Economics
Eli Lilly is a research-based pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines globally. Revenue flows primarily from branded prescription drug sales to wholesalers, pharmacies, and healthcare providers, supplemented by collaboration and licensing fees and royalties from partner-developed medicines.18
Revenue Segments
Lilly reports revenue in two geographic segments — the U.S. and International — and four therapeutic areas. As of Q2 2026, the Cardiometabolic Health segment is overwhelmingly dominant, generating approximately $15.8 billion in Q1 2026 alone, compared to Lilly's $19.8 billion total Q1 revenue — meaning cardiometabolic is roughly 80% of total sales.19 Within cardiometabolic:
- Mounjaro (tirzepatide, diabetes): FY 2025 revenue of $22.965 billion (+99% YoY), with Q4 2025 reaching $7.409 billion (+110%).1
- Zepbound (tirzepatide, obesity): FY 2025 revenue of $13.542 billion (+175% YoY), with Q4 2025 at $4.261 billion (+123%).1
- Foundayo (orforglipron, obesity pill): FDA approved April 1, 2026; very early commercial ramp in Q2 2026.2
The remaining ~20% of revenue comes from Oncology (Verzenio/abemaciclib for breast cancer, Jaypirca for blood cancers), Neuroscience (Kisunla/donanemab for Alzheimer's disease, Emgality for migraine), and Immunology (Taltz/ixekizumab for psoriasis). These segments collectively grew 160% in Q1 2026 YoY — indicating the non-GLP-1 portfolio is also scaling meaningfully.4
Unit Economics & Moat
Lilly's pricing power derives from regulatory exclusivity (patent protection on tirzepatide extends deep into the 2030s for key claims), differentiated clinical efficacy (tirzepatide's dual mechanism shows superior weight loss versus GLP-1-only semaglutide in head-to-head trials), and manufacturing scale barriers. Operating margins have expanded dramatically: the company guided FY 2026 operating margin (on a non-GAAP basis) to 49.0–50.5%, up from its prior guidance of 47.0–48.5% — levels rarely seen in large-cap pharma.3
Growth Motions
Three growth levers are running in parallel. First, volume growth in established GLP-1 markets (the U.S. remains supply-constrained relative to demand). Second, geographic expansion, particularly in Europe, China, and Japan as Lilly builds manufacturing capacity locally.5 Third, pipeline expansion via acquisition: in 2026 alone, Lilly agreed to acquire Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics, adding mRNA, gene therapy, and next-generation small-molecule capabilities.4 The company has also launched LillyDirect — a direct-to-consumer platform enabling patients to access prescriptions and home delivery, reducing channel friction.18
Price History & Technicals
| Metric | Value | Notes |
|---|---|---|
| Last Close (Aug 18, 2026) | $1,183.16 | Source: Investing.com9 |
| 52-Week High | $1,249.45 | Reached in recent months on earnings momentum9 |
| 52-Week Low | $685.15 | ~Aug 2025 trough before guidance raises9 |
| YTD Change | +60.9% | Significant outperformance vs. S&P 5009 |
| Shares Outstanding | ~891.74M | As of mid-2025 SEC filing20 |
| Market Capitalization | ~$1.06T | At last close price9 |
| Stock Splits (Historical) | 5 splits | Adjusted for all splits in historical data9 |
| Exchange | NYSE | Ticker: LLY |
LLY shares have delivered one of the pharmaceutical sector's most remarkable multi-year runs. From approximately $100 (split-adjusted) in 2018, the stock has risen to $1,183 as of August 2026 — a roughly 12× gain over eight years, driven almost entirely by the commercial emergence of tirzepatide.9 The 52-week range of $685–$1,249 reflects a stock that has more than doubled from its August 2025 lows as the growth story has re-accelerated on beat-and-raise earnings quarters.9
The stock made history when Lilly became the first pharmaceutical company to cross the $1 trillion market capitalization threshold, a milestone driven by back-to-back blowout earnings reports and consecutive guidance raises.9 More recently, LLY hit an intraday all-time high of $1,249.45 within its current 52-week range.9
From a technical perspective, LLY is trading at $1,183 — roughly 5.3% below its 52-week high — after a strong YTD advance. The stock's ability to consolidate near highs rather than giving back significant gains suggests institutional accumulation rather than distribution. The consensus average price target of $1,270 implies modest additional upside of ~7.3% from current levels, suggesting the stock is fairly-to-fully valued at current earnings trajectory but not yet pricing in meaningful pipeline optionality from retatrutide, orforglipron-for-diabetes, or Alzheimer therapies.21
Financial Statements & Guidance
Income Statement Summary
| Metric | FY 2023 | FY 2024 | FY 2025 | Q2 2026 |
|---|---|---|---|---|
| Revenue | ~$34.1B | $45.0B | $65.18B | $23.0B |
| Revenue Growth YoY | — | +32% | +45% | +48% |
| Net Income | ~$5.2B | $10.6B | $20.64B | — |
| Net Income Growth YoY | — | +102% | +95% | — |
| Reported EPS (diluted) | — | — | — | $7.94 |
| Non-GAAP EPS (diluted) | — | — | — | $8.38 |
| Profit Margin | ~15% | 24% | ~32% | — |
Sources: Eli Lilly investor relations, SEC filings.1213 FY 2023 revenue derived from growth rates implied by FY 2024 reported +32% growth; marked approximate. Q2 2026 net income not separately reported in sources available at time of writing.
Balance Sheet Highlights
As of the fiscal quarter ending December 2025, Eli Lilly reported total long-term debt of approximately $42.5 billion, reflecting its aggressive capital deployment into manufacturing expansion and business development acquisitions.20 Total assets stood at $112.48 billion in Q1 2025, with total liabilities of $85.94 billion.20 Lilly authorized a $15 billion share repurchase program in December 2024; as of June 30, 2025, $13.11 billion remained unused — a significant shareholder-return runway.20
FY 2026 Forward Guidance (Updated August 2026)
| Metric | Updated Guide (Aug 2026) | Prior Guide |
|---|---|---|
| Full-Year Revenue | $85.0B – $87.0B | $82.0B – $85.0B |
| Non-GAAP EPS | $35.50 – $36.50 | Prior midpoint ~$33 |
| Non-GAAP Operating Margin | 49.0% – 50.5% | 47.0% – 48.5% |
The updated guidance was announced alongside Q2 2026 earnings on August 5, 2026. This is the second guidance raise in 2026, with the first raise following Q1 2026 results in April.38 The $2.78 midpoint EPS raise was partially offset by $3.03 of acquired in-process R&D charges from Q2 business development activity (the pipeline acquisitions noted above).13
Sell-Side View
Eli Lilly carries one of the strongest sell-side endorsements in large-cap pharmaceuticals, with approximately 81% of covering analysts rating the stock Buy or Outperform as of August 2026.21 The 29-analyst S&P Global consensus price target stands at $1,270, implying modest upside from current levels, with the high-end target at $1,600 and the low at $850 — indicating significant dispersion around the pace of GLP-1 market expansion and competitive dynamics.21
Selected Analyst Actions
| Firm | Rating | Price Target | Date / Note |
|---|---|---|---|
| Morgan Stanley (Terence Flynn) | Overweight | $1,327 | Raised from $1,313; cites tirzepatide durability21 |
| Deutsche Bank | Buy | $1,200 | Retained post Q4 2025 results; strong FY 2026 projections21 |
| Barclays | Overweight | $1,400 | Raised May 2026; tirzepatide momentum cited22 |
| S&P Global Consensus | Buy | $1,270 avg | 29 analysts; high $1,600 / low $85021 |
| Overall Wall Street Consensus | Buy / Outperform | $1,310.90 avg | 35 brokerage firms; 23 Buy, 2 Sell21 |
Analyst conviction is high but the wide PT dispersion ($850 to $1,600) reflects genuine uncertainty around three swing factors: (1) the pace and pricing of international GLP-1 rollout, (2) the commercial uptake of Foundayo as an oral alternative, and (3) competitive responses from Novo Nordisk and emerging rivals.2122 Bears within the sell-side community focus on the valuation premium Lilly carries relative to comparable pharma companies and the risk of a multiple compression if any of the three key pillars (tirzepatide growth, Foundayo, pipeline) disappoint.
The Q2 2026 beat — revenue $2B above consensus, EPS $2.31 above — drove renewed upward revisions to full-year estimates and at least two target increases among top-tier banks following the August 5, 2026 report.13 The quality of the beat (broad-based across products and geographies, not a one-time item) gives the buy-side confidence that the guidance raise reflects durable operating momentum rather than a pull-forward.
Partnerships, Customers & Suppliers
In July 2026, Resilience and Lilly announced a $750 million joint investment to expand Resilience's advanced biologic manufacturing in the Cincinnati, Ohio region, adding capacity for Lilly's KwikPen injectable device for diabetes and obesity medicines. Full operations expected early 2027.5
Lilly is investing $200 million in Beijing-based CDMO Pharmaron as part of a broader $3 billion China manufacturing commitment, targeting local production of orforglipron oral solid dosage forms for the Chinese market.5
In October 2025, Lilly committed over $1 billion to India contract manufacturing partners, leveraging India's skilled pharmaceutical workforce and established CDMO infrastructure to build additional GLP-1 supply capacity.5
Agreed in 2026 as part of Lilly's business development wave, Orna brings circular RNA technology that could power next-generation gene therapies in cardiometabolic and other indications.4
Agreed to acquire in Q2 2026 as part of Lilly's accelerating business development. Centessa adds novel small-molecule drug assets across multiple therapeutic areas to the Lilly pipeline.4
Both agreed in Q2 2026 business development activity, adding early-stage oncology and gene therapy capabilities. CEO David Ricks noted Lilly "remains active in business development while maintaining discipline."14
In November 2025, Lilly announced a $3 billion manufacturing facility to be constructed in the Leiden Bio Science Park, Netherlands, aimed at securing European GLP-1 supply capacity.5
Lilly's proprietary direct-to-patient digital platform allows consumers to obtain prescriptions and home delivery for Zepbound and Foundayo, reducing channel friction and improving access — part of Lilly's move toward a direct consumer model.18
Lilly's partnership strategy reflects two priorities: rapidly scaling manufacturing capacity to eliminate the supply shortfall constraining GLP-1 revenues, and building a diversified early-stage pipeline to reduce long-term dependence on tirzepatide. The manufacturing build-out spans the U.S., Europe, China, Japan, and India — a global footprint designed to serve both the insulin and GLP-1 franchises.5
Competition
The GLP-1 obesity and diabetes market is currently a de facto duopoly between Eli Lilly (tirzepatide) and Novo Nordisk (semaglutide), with both companies generating extraordinary revenues that dwarf any other pharmaceutical franchise. Lilly's tirzepatide franchise pulled ahead of Novo's semaglutide franchise in 2025 on combined revenue: $36.5B vs. approximately $33B for Ozempic/Wegovy combined.1
| Company | Status | Key GLP-1 Product(s) | Differentiator vs. Lilly | Notable Metric |
|---|---|---|---|---|
| Novo Nordisk (NVO) | Public (Copenhagen) | Ozempic, Wegovy (semaglutide); Rybelsus (oral) | First-mover; Rybelsus is already-approved oral semaglutide; broader international reach | ~$33B combined semaglutide revenue FY 20251 |
| Pfizer (PFE) | Public (NYSE) | Pipeline (Metsera acquisition) | Shifted strategy post-failure of two oral GLP-1 pills; now rebuilding via Metsera acquisition; diversified oncology/vaccine base | No approved GLP-1 obesity product as of Aug 202623 |
| Sanofi (SNY) | Public (Euronext/NYSE) | Soliqua (insulin glargine + lixisenatide) | Combination fixed-ratio product for type 2 diabetes; not in obesity competition | Niche positioning in T2D only23 |
| Viking Therapeutics | Public (Nasdaq: VKTX) | VK2735 (dual GIP/GLP-1, oral and injectable) | Clinical-stage challenger with compelling Phase 2 weight-loss data; both injectable and oral forms in development | Clinical stage; no approved products23 |
| Amgen (AMGN) | Public (Nasdaq) | MariTide (AMG 133) | Monthly injectable GIP antagonist/GLP-1 agonist; different mechanism; in Phase 3 | Phase 3 readout expected 2026–202723 |
Lilly's primary competitive moat rests on tirzepatide's dual mechanism (GIP + GLP-1 agonism), which has demonstrated superior weight loss versus semaglutide GLP-1-only therapy in head-to-head data. In Q1 2026, Lilly's Cardiometabolic Health business generated approximately $15.8 billion versus Novo Nordisk's Diabetes and Obesity Care segment at approximately $14.2 billion — a market share gap that widened YoY.19
The moat is most durable in the injectable premium segment and in the newly opened oral GLP-1 segment, where Foundayo (approved April 2026) has a meaningful convenience advantage: unlike Novo's Rybelsus (which must be taken fasting), Foundayo requires no food or water restrictions.2 This positions Lilly favorably for the oral GLP-1 segment that analysts project could be far larger than the injectable market due to patient preference and lower needle aversion.
Where Lilly's moat is weaker: international markets where Novo has longer-established semaglutide infrastructure; compound pharmacy competition where cheaper alternatives erode market access; and the long-run risk that next-generation once-weekly or once-monthly treatments (e.g., Amgen's MariTide) could eventually displace tirzepatide's clinical edge. Lilly's response — aggressive manufacturing expansion and a deep acquisitions pipeline — is the appropriate strategic answer, but execution risk is real at this pace of capital deployment.54
Risks & the Bear Case
Mounjaro and Zepbound together generated ~65% of Q2 2026 total revenue. A safety signal, label update, or significant pricing reversal on tirzepatide would cascade through the entire income statement.6
Lilly filed the first U.S. patent suits against 14 generic challengers of Mounjaro and Zepbound in August 2026. Once tirzepatide patents expire — likely mid-2030s — biosimilar entry could dramatically compress revenue and margins.7
Q1 2026 revenue growth was "partially offset by lower realized prices" from Mounjaro and Zepbound. IRA drug-price negotiations and evolving payer contracting dynamics represent structural margin headwinds.8
FDA-authorized compounders supplying cheaper versions of tirzepatide represent near-term demand leakage. Lilly is litigating aggressively, but the legal outcome and its commercial impact remain uncertain.7
Lilly is deploying billions simultaneously across U.S., Netherlands, China, Japan, and India manufacturing sites. Any construction delays, regulatory setbacks, or quality issues at scale could cause supply shortfalls or cost overruns.5
Viking Therapeutics' VK2735, Amgen's MariTide, and other pipeline assets could deliver superior efficacy or convenience data, eroding Lilly's clinical differentiation advantage in the 2027–2030 timeframe.23
At a ~$1 trillion market cap and trading at a substantial premium to large-cap pharma peers, any miss on guidance, clinical failure, or macro shock could trigger sharp de-rating. The stock carries a lot of future growth already priced in.9
All GLP-1 drugs carry label risks (gastrointestinal side effects, rare thyroid C-cell tumor signals in rodents). A post-market safety signal from any class member could trigger prescribing caution, label changes, or demand reduction across the entire class.24
Bear Thesis Deep Dive
The strongest bearish argument against LLY at current valuations is not that the business is broken — it clearly is exceptional. The bear case is that the market is extrapolating peak tirzepatide revenue forward indefinitely, without adequately pricing in the multiple compressors that loom over the 2028–2035 horizon.
First, pricing compression is already underway. Lilly explicitly noted in Q1 2026 that revenue growth was "partially offset by lower realized prices" — meaning even at double-digit volume growth, net pricing per unit is declining.8 As Medicare and commercial payers gain leverage (particularly post-IRA), this trend is likely to intensify. If realized prices decline 10–15% annually while volume grows 20%, the net revenue math becomes much less attractive than gross volume suggests.
Second, the generic threat is real and accelerating. Fourteen companies filed Paragraph IV certifications challenging Mounjaro and Zepbound patents by August 2026, triggering Lilly's first U.S. patent suits.7 While Lilly's patent portfolio is extensive and the litigation will take years to resolve, the mere filing signals that generics are actively preparing for entry. When biosimilar tirzepatide eventually reaches the market, the pricing collapse could be severe — as seen historically with other injectable biologics that lost 40–70% of net revenue within two years of generic entry.
Third, business development acquisitions carry integration risk and IPR&D charges. Lilly's four Q2 2026 acquisitions generated $3.03 in non-GAAP EPS charges — diluting the headline guidance raise by more than its underlying business improvement.13 As Lilly's deal pace and deal size continue to increase (per CEO commentary), IPR&D headwinds will recur, and not all acquired pipelines will succeed.
Catalysts — Recent & Upcoming
Recent Catalysts (May–August 2026)
Upcoming Watch List
| Event | Expected Timing | Significance |
|---|---|---|
| Q3 2026 Earnings | ~October/November 2026 | Next beat-and-raise opportunity; will show Foundayo commercial ramp and tirzepatide volume trajectory13 |
| Foundayo (orforglipron) for Type 2 Diabetes — FDA Decision | 2026 or 2027 | Positive Phase 3 data reported; FDA submission expected; could massively expand oral GLP-1 market4 |
| Retatrutide Phase 3 Readout (Type 2 Diabetes) | 2026–2027 | Positive Phase 3 data already reported; NDA submission timeline to be disclosed4 |
| Jaypirca + venetoclax + rituximab FDA Decision | 2026 | Positive Phase 3 data in relapsed/refractory CLL; next major oncology approval candidate4 |
| Medicare GLP-1 Coverage Expansion | 2026 (pending) | Any expansion of Medicare coverage for obesity drugs would unlock massive new demand pool25 |
| Patent Litigation Outcomes | Multi-year | 14 pending patent suits vs. generic challengers; any adverse ruling would be a material negative catalyst7 |
References
- Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance Eli Lilly Investor Relations · February 2026
- FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Eli Lilly Investor Relations · April 1, 2026
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress PR Newswire / Eli Lilly · August 5, 2026
- Lilly Q2 2026 IR press release — pipeline progress and business development Eli Lilly Investor Relations · August 5, 2026
- Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply BusinessWire · July 30, 2026
- Eli Lilly (LLY) Stock Price & Overview — revenue segment breakdown Stock Analysis · August 2026
- Eli Lilly Sues Mounjaro, Zepbound Generics as GLP-1 Disputes Multiply Law.com / Delaware Business Court · August 14, 2026
- Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket (Q1 2026) CNBC · April 30, 2026
- Eli Lilly Stock Price Today | NYSE: LLY Live Investing.com · August 18, 2026
- Eli Lilly and Company Wikipedia · Accessed August 2026
- A history of… Eli Lilly & Co Pharmaphorum · Accessed August 2026
- Lilly reports full Q4 2024 financial results and provides 2025 guidance Eli Lilly Investor Relations · February 2025
- Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge (Q2 2026) CNBC · August 5, 2026
- Eli Lilly (LLY) Q2 2026 Earnings Call Transcript The Motley Fool · August 2026
- What is Brief History of Eli Lilly Company? PortersFiveForce.com · Accessed August 2026
- Company Leadership Eli Lilly and Company · Accessed August 2026
- LLY Q2 Deep Dive: Key Products and Pipeline Expansion Yahoo Finance · August 2026
- Eli Lilly and: Business Model, SWOT Analysis, and Competitors 2026 PitchGrade · 2026
- GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk Yahoo Finance · 2026
- Eli Lilly (LLY) Balance Sheet — shares outstanding, debt, total assets Stock Analysis · August 2026
- Eli Lilly and Company (LLY) Stock Forecast & Price Targets Stock Analysis · August 2026
- Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show 24/7 Wall St. · May 5, 2026
- GLP-1s: Lilly, Novo, Pfizer look to new weight loss drugs CNBC · June 13, 2026
- Maximizing GLP-1 Market Exclusivity: Leveraging Patent Term Extension and NCE Exclusivity DrugPatentWatch · 2026
- Novo Nordisk, Eli Lilly roll out obesity pills, prepare for Medicare coverage CNBC · June 8, 2026